Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corcept Therapeutics
The primary outcome measures of the study are 1) to assess the efficacy of relacorilant based on blood pressure control at Week 22 compared with placebo, and 2) to assess the safety of relacorilant based on adverse events. Patients will be randomized in a 1:1 ratio to treatment with relacorilant (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks. Patients who complete the study may also be eligible to roll over into an extension study.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Shows lack of cortisol suppression on dexamethasone suppression test
Suppressed or low early-morning adrenocorticotropic hormone (ACTH) levels
A radiologically confirmed adrenal lesion
Has IGT or DM
Has uncontrolled HTN
You may not be if
Has severe, uncontrolled HTN
Has poorly controlled DM
Has DM Type 1
Has significantly abnormal liver test results or severe renal insufficiency
Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
Clareo Health | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
